Eboni I Lance1, Kira E Lanier2, T Andrew Zabel3, Anne M Comi4. 1. Department of Neurodevelopmental Medicine, Kennedy Krieger Institute, Baltimore, Maryland; Department of Pediatrics, Johns Hopkins School of Medicine, Baltimore, Maryland; Department of Neurology, Johns Hopkins School of Medicine, Baltimore, Maryland. 2. Department of Neurodevelopmental Medicine, Kennedy Krieger Institute, Baltimore, Maryland. 3. Department of Neuropsychology, Kennedy Krieger Institute, Baltimore, Maryland. 4. Department of Neurodevelopmental Medicine, Kennedy Krieger Institute, Baltimore, Maryland; Department of Pediatrics, Johns Hopkins School of Medicine, Baltimore, Maryland; Department of Neurology, Johns Hopkins School of Medicine, Baltimore, Maryland. Electronic address: comi@kennedykrieger.org.
Abstract
BACKGROUND: Sturge-Weber syndrome is characterized by a facial port-wine birthmark, vascular eye abnormalities, and a leptomeningeal angioma. Attention and behavioral issues are common in Sturge-Weber syndrome. However, literature evidence for stimulant treatment is minimal. This study evaluates stimulant medication safety and efficacy in individuals with Sturge-Weber syndrome. METHODS: The research database of the Hunter Nelson Sturge-Weber Center (n = 210 subjects in the database) was reviewed for stimulant use. Twelve patients (mean age 10.5 years, age range 4 to 21 years) on stimulants were seen between 2003 and 2012. A retrospective chart review obtained comorbid diagnoses, stimulant type and dosage, medication side effects, vital signs, and medication efficacy. RESULTS: All 12 patients had brain involvement (unilateral, nine; bilateral, three). Additional comorbidities included epilepsy (twelve), hemiparesis (eight), headaches (eight), and vision deficits (six). Eight patients reported side effects, primarily appetite suppression (four) and headaches (three). There were no statistically significant changes in weight or blood pressure 6 months after medication initiation. Medication efficacy was subjectively reported in 11 patients. Seven patients remained on stimulants at their most recent follow-up visit. CONCLUSIONS: This study preliminarily evaluates stimulant medication use in a small group of Sturge-Weber syndrome patients. Stimulants were tolerated and effective in most subjects. Side effects were mostly minor and medication did not negatively affect growth or vital signs. Stimulant medication may be a safe and effective intervention for Sturge-Weber syndrome children with attention issues/attention deficit hyperactivity disorder. Further studies with larger sample sizes are needed.
BACKGROUND:Sturge-Weber syndrome is characterized by a facial port-wine birthmark, vascular eye abnormalities, and a leptomeningeal angioma. Attention and behavioral issues are common in Sturge-Weber syndrome. However, literature evidence for stimulant treatment is minimal. This study evaluates stimulant medication safety and efficacy in individuals with Sturge-Weber syndrome. METHODS: The research database of the Hunter Nelson Sturge-Weber Center (n = 210 subjects in the database) was reviewed for stimulant use. Twelve patients (mean age 10.5 years, age range 4 to 21 years) on stimulants were seen between 2003 and 2012. A retrospective chart review obtained comorbid diagnoses, stimulant type and dosage, medication side effects, vital signs, and medication efficacy. RESULTS: All 12 patients had brain involvement (unilateral, nine; bilateral, three). Additional comorbidities included epilepsy (twelve), hemiparesis (eight), headaches (eight), and vision deficits (six). Eight patients reported side effects, primarily appetite suppression (four) and headaches (three). There were no statistically significant changes in weight or blood pressure 6 months after medication initiation. Medication efficacy was subjectively reported in 11 patients. Seven patients remained on stimulants at their most recent follow-up visit. CONCLUSIONS: This study preliminarily evaluates stimulant medication use in a small group of Sturge-Weber syndromepatients. Stimulants were tolerated and effective in most subjects. Side effects were mostly minor and medication did not negatively affect growth or vital signs. Stimulant medication may be a safe and effective intervention for Sturge-Weber syndromechildren with attention issues/attention deficit hyperactivity disorder. Further studies with larger sample sizes are needed.
Authors: Jennifer Reesman; Robert Gray; Stacy J Suskauer; Lisa M Ferenc; Eric H Kossoff; Doris D M Lin; Elizabeth Turin; Anne M Comi; Patrick J Brice; T Andrew Zabel Journal: J Child Neurol Date: 2009-04-08 Impact factor: 1.987
Authors: Laura A Hatfield; Nathan E Crone; Eric H Kossoff; Joshua B Ewen; Paula L Pyzik; Doris D M Lin; Thomas M Kelley; Anne M Comi Journal: Epilepsia Date: 2007-01 Impact factor: 5.864
Authors: Elizabeth Turin; Marco A Grados; Elaine Tierney; Lisa M Ferenc; Andrew Zabel; Anne M Comi Journal: J Nerv Ment Dis Date: 2010-12 Impact factor: 2.254
Authors: Alejandro J De la Torre; Aimee F Luat; Csaba Juhász; Mai Lan Ho; Davis P Argersinger; Kara M Cavuoto; Mabel Enriquez-Algeciras; Stephanie Tikkanen; Paula North; Craig N Burkhart; Harry T Chugani; Karen L Ball; Anna Lecticia Pinto; Jeffrey A Loeb Journal: Pediatr Neurol Date: 2018-04-18 Impact factor: 3.372
Authors: Alison J Sebold; Alyssa M Day; Joshua Ewen; Jack Adamek; Anna Byars; Bernard Cohen; Eric H Kossoff; Tomoyuki Mizuno; Matthew Ryan; Jacqueline Sievers; Lindsay Smegal; Stacy J Suskauer; Cameron Thomas; Alexander Vinks; T Andrew Zabel; Adrienne M Hammill; Anne M Comi Journal: Pediatr Neurol Date: 2020-11-02 Impact factor: 3.372